BioLineRx (NASDAQ:BLRX) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

BioLineRx (NASDAQ:BLRX) posted its earnings results on Monday. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19, Zacks reports. BioLineRx had a negative return on equity of 49.74% and a negative net margin of 45.34%.The firm had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.67 million.

BioLineRx Price Performance

Shares of NASDAQ:BLRX opened at $3.50 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.87 and a current ratio of 2.06. BioLineRx has a one year low of $2.30 and a one year high of $14.70. The company has a market capitalization of $15.23 million, a PE ratio of -1.45 and a beta of 1.34. The stock has a fifty day moving average of $3.68 and a 200-day moving average of $3.98.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.00.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.